Replies to post #54931 on Biotech Values

[DewDiligence]

>PP – If I-hub had a recommend button I would have hit it on this post, my sentiment exactly!<

I’m glad someone else gets it!

Kanzer comes across on the CC’s as a moron, but he’s executing his plan to perfection. Reverse merge into a corporate shell; register insiders’ shares for resale, but wait several months to allow time to hoodwink investors into thinking the company has cutting-edge science; talk up the company’s “products” by comparing them to big-selling drugs; sell shares; issue options to repeat the whole process—all without the inconvenience of having the business vetted in an IPO.

William Carter of Hemispherx would be proud.

[DewDiligence]

>PP …I think they have about 10 patients in an open label study for IPF and other drugs in the class aren't exactly SOC for IPF…<

I figured that, amid the incessant babbling, you would get a kick out of Kanzer’s citing ITMN as competition.